Connexion
E-mail
Mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

Accueil Zonebourse  >  Actions  >  Euronext Paris  >  BOIRON    BOI   FR0000061129

BOIRON

(BOI)
  Rapport
Cours en temps réel. Temps réel Euronext Paris - 22/09 17:35:26
41.05 EUR   +3.92%
11/09BOIRON : Interview de Valérie Lorentz-Poinsot, Directrice générale de Boiron
10/09BOIRON : en hausse, un broker en soutien
CF
10/09BOIRON : en hausse, le plus dur est passé
AO
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéCommuniquésPublications officiellesActualités du secteurAnalyses ZonebourseRecommandations des analystes

Boiron : 2020 half year activity

share with twitter share with LinkedIn share with facebook
17/07/2020 | 11:35

(Unaudited data)

Cumulative Activity as of the end of june 2020














In thousands of euros 2019 2020 Variation at current exchange rates Variation at constant exchange rates
France 151 357 126 323 -16,5% -16,5%
Europe (excluding France) 55 330 54 485 -1,5% -0,8%
North America 40 661 61 365 +50,9% +47,4%
Other countries 9 370 11 460 +22,3% +35,6%
Group total 256 718 253 633 -1,2% -1,1%

 

In thousands of euros 2019 2020 Variation at current exchange rates Variation at constant exchange rates
Non-proprietary Homeopathic Medicines 133 214 110 055 -17,4% -17,5%
OTC Specialties 122 716 142 917 +16,5% +16,8%
Other 788 660 -16,2% -15,3%
Group total 256 718 253 633 -1,2% -1,1%

Activity by quarter (variation at current exchange rates)

In thousands of euros 1st quarter 2d quarter
  2019 2020 Var. 20/19 2019 2020 Var. 20/19
France 83 440 72 820 -12,7% 67 917 53 503 -21,2%
Europe (excluding France) 31 779 37 581 +18,3% 23 551 16 904 -28,2%
North America 23 580 40 272 +70,8% 17 081 21 094 +23,5%
Other countries 4 516 5 960 +32,0% 4 854 5 499 +13,3%
Group total 143 315 156 633 +9,3% 113 403 96 999 -14,5%

 

In thousands of euros 1st quarter 2d quarter
  2019 2020 Var. 20/19 2019 2020 Var. 20/19
Non-proprietary Homeopathic Medicines 69 067 61 722 -10,6% 64 147 48 334 -24,7%
OTC Specialties 73 845 94 619 +28,1% 48 871 48 298 -1,2%
Other 403 292 -27,3% 385 367 -4,6%
Group total 143 315 156 633 +9,3% 113 403 96 999 -14,5%

Sales growth

Sales in the second quarter of 2020 were down 14.5% versus 2019. In an already delicate context, the decline in sales in France worsened (down 21.2% vs. a drop of 12.7% in the first quarter) following decreased doctors' appointments and pharmacy visits during the health crisis. This impacted different countries in different ways: sales in Europe were down 28.2%, mainly in Russia and Italy, while sales grew 23.5% in North America.

Over the first half, sales were down 1.2%, as a result of two contrasting developments:

  • A 16.5% decline in business in France in non-proprietary medicines (down 21.0%) and specialties (down 6.6%)
  • International sales growth of 20.8%, mainly in North America

Furthermore, in France, we have produced over 50,000 liters of hydro-alcoholic solution, for which marketing authorization has been extended until the end of this year.

News

Following the significant drop in business in France, a reorganization plan was announced on 11 March. Given that meetings to negotiate with staff representatives could not take place during the lockdown, they began at the start of June and will continue until 14 October this year. A provision for the cost of this plan will be recorded in the first half financial statements, to be published on 9 September.

Despite the ongoing global health crisis, we have managed to maintain our production and distribution businesses, both in France and abroad, thanks to the commitment of all our employees. Administrative work was performed under remote working arrangements during the lockdown, and only commercial activities were temporarily impacted.

Outlook

Global business levels looking forward will depend on how the global health and economic situation progresses.

We believe that sales in France will continue to be impacted over the second half by the government's decision to delist non-proprietary medicines from French health insurance from 1st January 2021.

As such, we expect to see a decrease in sales and earnings in 2020.

We remain determined to continue our efforts to maintain the reimbursement of homeopathic medicines, reflecting the demand of the millions of patients who use them with satisfaction.

Laboratoires BOIRON


Our next update:
September 9, 2020: at market close, publication of 2020 half-year results.
Person responsible for financial information: Valérie Lorentz-Poinsot.
Contact for financial information: Fabrice Rey.
Investor relations: +33 (0) 4.78.45.63.43 - e-mail:
boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com



Cette publication dispose du service "Actusnews SECURITY MASTER".
- SECURITY MASTER Key : lG2flchvk5qYlmyaaMqam5WXaJmSkmOaZWPHlpNva8iZm3FomJhhacqYZm9lmGdu
- Pour contrôler cette clé : https://www.security-master-key.com.



Information réglementée :
Informations privilégiées :
- Communiqué sur comptes, résultats


Communiqué intégral et original au format PDF : https://www.actusnews.com/news/64328-boi-160720-ca-s1-2020-gb.pdf

© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com


© 2020 ActusNews
share with twitter share with LinkedIn share with facebook
Réagir à cet article
Réagir le premier
Publier
loader
Toute l'actualité sur BOIRON
11/09BOIRON : Interview de Valérie Lorentz-Poinsot, Directrice générale de Boi..
10/09BOIRON : en hausse, un broker en soutien
CF
10/09BOIRON : en hausse, le plus dur est passé
AO
10/09BOIRON : Réunion d'information du 10 septembre 2020
PU
10/09BOIRON : après le 'point bas', Oddo passe à l'achat
CF
10/09AVIS D'ANALYSTES DU JOUR : Bouygues, Cellnex, Faurecia, Novartis, Scor, Sunrise,..
09/09BOIRON : recul de -148% du résultat net pdg semestriel
CF
09/09BOIRON : Rapport semestriel 2020
PU
09/09BOIRON : Résultats semestriels 2020
PU
09/09BOIRON : Résultats du premier semestre 2020
AN
Plus d'actualités
Recommandations des analystes sur BOIRON
Plus de recommandations
Données financières
CA 2020 537 M 629 M -
Résultat net 2020 18,9 M 22,2 M -
Tréso. nette 2020 228 M 267 M -
PER 2020 38,0x
Rendement 2020 1,11%
Capitalisation 692 M 810 M -
VE / CA 2020 0,86x
VE / CA 2021 0,84x
Nbr Employés 3 500
Flottant 24,8%
Graphique BOIRON
Durée : Période :
BOIRON : Graphique analyse technique BOIRON | Zone bourse
Graphique plein écran
Tendances analyse technique BOIRON
Court TermeMoyen TermeLong Terme
TendancesHaussièreHaussièreNeutre
Evolution du Compte de Résultat
Consensus
Vente
Achat
Recommandation moyenne CONSERVER
Nombre d'Analystes 3
Objectif de cours Moyen 40,07 €
Dernier Cours de Cloture 41,05 €
Ecart / Objectif Haut -1,34%
Ecart / Objectif Moyen -2,40%
Ecart / Objectif Bas -3,29%
Révisions de BNA
Dirigeants
Nom Titre
Valérie Lorentz-Poinsot Chief Executive Officer & Director
Thierry Boiron Chairman
Patrice Varraut Chief Operating Officer
Eric Lambert Chief Financial & Administrative Officer
Hervé Coulpier Chief Technologic Officer
Secteur et Concurrence
Var. 1janvCapitalisation (M$)
BOIRON8.52%812
BEIJING TONGRENTANG CO., LTD0.96%5 847
CANOPY GROWTH CORPORATION-23.51%5 828
CURALEAF HOLDINGS, INC.18.46%4 787
DONG-E-E-JIAO CO.,LTD.17.27%3 961
TRULIEVE CANNABIS CORP.56.21%2 324